SUCNR1 and Cognitive impairment: If SUCNR1 antagonism or deficiency were found to attenuate neuroinflammation and cognitive deficits in this model, it would strongly support receptor-mediated signalling—rather than nonspecific metabolic toxicity—as a primary mechanism and would highlight SUCNR1 as a potential therapeutic target in SAE.